Communiqués XORTX Therapeutics Inc.

Actions

XRTX

CA98420Q4051

Recherche biotechnologique et médicale

Marché Fermé - Toronto S.E. 21:55:34 31/08/2026			Varia. 5j.	Varia. 1 janv.
3,190 ^CAD	+4,59%		+14,34%	-17,14%

15/08	XORTX Therapeutics Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
31/07	XORTX Therapeutics Inc. annonce la démission d'Anthony Giovinazzo de son poste d'administrateur	CI

Communiqués

31/08	XORTX Announces Termination and Postponement of Investor Relations Program	AQ
28/08	XORTX Announces Termination and Postponement of Investor Relations Program	AQ
31/07	XORTX Announces Director Resignation	AQ
29/07	XORTX Appoints New Director	AQ
15/06	XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO	AQ
12/06	XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange	AQ
18/05	E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering	AQ
14/05	XORTX Announces US$5 Million Public Offering	AQ
21/04	XORTX Meets Nasdaq Continued Listing Requirements	AQ
13/04	XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset	AQ
10/04	XORTX Therapeutics : Investor Presentation	PU
26/03	XORTX Announces Results of Annual and Special Meeting of Shareholders	AQ
26/03	XORTX Announces Change of Effective Date of Share Consolidation	AQ
25/03	XORTX Announces Share Consolidation	AQ
24/03	XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General Meeting	AQ
18/03	XORTX Announces Substitute Director Nominees for its Upcoming Annual and Special Meeting of Shareholders	AQ
13/03	XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote “For” the Share Consolidation	AQ
05/03	XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders	AQ
13/02	XORTX Therapeutics : Investor Presentation	PU
05/02	XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems	AQ
07/01	XORTX Therapeutics : Investor Presentation	PU
01/01	XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update	AQ
26/11	XORTX Therapeutics : Investor Presentation	PU
29/10/25	XORTX Announces Closing of US$1.1 Million Registered Direct Offering	AQ
21/10/25	XORTX Announces Pricing of US$1.1 Million Registered Direct Offering	AQ